Fatal Myocarditis and Rhabdomyositis in a Patient With Stage IV Melanoma Treated With Combined Ipilimumab and Nivolumab

Current Oncology- Canada

doi 10.3747/co.26.4381

Full Text

Abstract

Available in

Date

June 25, 2019

Authors

Publisher

MultiMed Inc.

Related search

Severe Hemophagocytic Lymphohistiocytosis in a Melanoma Patient Treated With Ipilimumab + Nivolumab

Journal for ImmunoTherapy of Cancer

English

Panhypopituitarism in Metastatic Melanoma Patient Treated With Ipilimumab and Pembrolizumab

Journal of Cutaneous Immunology and Allergy

2019

English

Ipilimumab Combined With Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?

Clinical Cancer Research

Cancer Research

Oncology

2016

English

Paraneoplastic Hyperleucocytosis in a Melanoma Patient After Initiation of Ipilimumab and Nivolumab Combination Therapy

Journal for ImmunoTherapy of Cancer

English

Pneumocystis Jirovecii Pneumonia in a Patient With Melanoma Treated With Infliximab and Corticosteroids for Ipilimumab-Associated Colitis

Global Dermatology

2016

English

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient With Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome

Case Reports in Oncological Medicine

Oncology

2018

English

Scalp Melanoma Treated With Ipilimumab in Elderly Patient: A Complete Response to Treatment—Case Report

Journal of Pharmacy and Pharmacology

2017

English

Correction To: Prolonged Stable Disease in a Uveal Melanoma Patient With Germline MBD4 Nonsense Mutation Treated With Pembrolizumab and Ipilimumab

English

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma

Journal of Clinical Oncology

English

Amanote Research

Fatal Myocarditis and Rhabdomyositis in a Patient With Stage IV Melanoma Treated With Combined Ipilimumab and Nivolumab

Current Oncology- Canada

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Severe Hemophagocytic Lymphohistiocytosis in a Melanoma Patient Treated With Ipilimumab + Nivolumab

Panhypopituitarism in Metastatic Melanoma Patient Treated With Ipilimumab and Pembrolizumab

Ipilimumab Combined With Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?

Paraneoplastic Hyperleucocytosis in a Melanoma Patient After Initiation of Ipilimumab and Nivolumab Combination Therapy

Pneumocystis Jirovecii Pneumonia in a Patient With Melanoma Treated With Infliximab and Corticosteroids for Ipilimumab-Associated Colitis

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient With Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome

Scalp Melanoma Treated With Ipilimumab in Elderly Patient: A Complete Response to Treatment—Case Report

Correction To: Prolonged Stable Disease in a Uveal Melanoma Patient With Germline MBD4 Nonsense Mutation Treated With Pembrolizumab and Ipilimumab

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma